Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics by Marek CJ et al.
BioMed CentralComparative Hepatology
ssOpen AcceResearch
Low affinity glucocorticoid binding site ligands as potential 
anti-fibrogenics
Carylyn J Marek*1, Karen Wallace1,2, Elaine Durward1, Matthew Koruth1, 
Val Leel1, Lucy J Leiper1 and Matthew C Wright1,2
Address: 1Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK and 2Institute of Cellular Medicine, Newcastle 
University, Framlington Place, Newcastle Upon Tyne, UK
Email: Carylyn J Marek* - c.j.marek@abdn.ac.uk; Karen Wallace - karen.wallace@ncl.ac.uk; Elaine Durward - e.durward@abdn.ac.uk; 
Matthew Koruth - Matthew.Koruth@arh.grampian.scot.nhs.uk; Val Leel - m.c.wright@ncl.ac.uk; Lucy J Leiper - l.leiper@abdn.ac.uk; 
Matthew C Wright - m.c.wright@ncl.ac.uk
* Corresponding author    
Abstract
Background: Pregnane X receptor (PXR) agonists inhibit liver fibrosis. However, the rodent PXR activator
pregnenolone 16α carbonitrile (PCN) blocks, in vitro, hepatic stellate cell-to-myofibroblast trans-differentiation
and proliferation in cells from mice with a disrupted PXR gene, suggesting there is an additional anti-fibrogenic
drug target for PCN. The role of the low affinity glucocorticoid binding site (LAGS) – which may be identical or
associated with the progesterone receptor membrane component 1 (PGRMC1) – in mediating this anti-fibrogenic
effect has been examined, since binding of dexamethasone to the LAGS in liver microsomal membranes has
previously been shown to be inhibited by PCN.
Results: Quiescent rat and human hepatic stellate cells (HSC) were isolated from livers and cultured to generate
liver myofibroblasts. HSC and myofibroblasts expressed PGRMC1 as determined by RT-PCR and Western
blotting. Quiescent rat HSC also expressed the truncated HC5 variant of rPGRMC1. Rat PGRMC1 was cloned
and expression in COS-7 cells gave rise to specific binding of radiolabelled dexamethasone in cell extracts that
was inhibited by PCN, suggesting that PGRMC1 may be identical to LAGS or activates LAGS binding activity. Liver
microsomes were used to screen a range of structurally related compounds for their ability to inhibit radiolabelled
dexamethasone binding to rat LAGS. These compounds were also screened for their ability to activate rat and
human PXR and to inhibit rat HSC-to-myofibroblast trans-differentiation/proliferation. A compound (4
androstene-3-one 17β-carboxylic acid methyl ester) was identified which bound rat LAGS with high affinity and
inhibited both rat and human HSC trans-differentiation/proliferation to fibrogenic myofibroblasts without
showing evidence of rat or human PXR agonism. However, despite potent anti-fibrogenic effects in vitro, this
compound did not modulate liver fibrosis severity in a rat model of liver fibrosis. Immunohistochemical analysis
showed that rat liver myofibroblasts in vivo did not express rPGRMC1.
Conclusion: LAGS ligands inhibit HSC trans-differentiation and proliferation in vitro but show little efficacy in
inhibiting liver fibrosis, in vivo. The reason(s) for this disparity is/are likely associated with an altered myofibroblast
phenotype, in vitro, with expression of rPGMRC1 in vitro but not in vivo. These data emphasize the limitations of
in vitro-derived myofibroblasts for predicting their activity in vivo, in studies of fibrogenesis. The data also
demonstrate that the anti-fibrogenic effects of PCN in vivo are likely mediated entirely via the PXR.
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Liver fibrosis is a common response to chronic liver dam-
age that at present does not have a therapeutic option yet.
The predicted increase in chronic liver disease (e.g., hepa-
titis C infection, non alcoholic steatohepatitis) means that
liver fibrosis will be an increasing clinical problem in the
future [1]. Liver fibrosis is primarily dependent on the
proliferation and activity of myofibroblasts typically iden-
tified through their expression of α-smooth muscle actin
[1]. These cells are derived from the trans-differentiation
of hepatic stellate cells (HSC) in response to damage
although they may also be generated from the trans-differ-
entiation of other cell types [1]. Nonetheless, the liver
myofibroblast is primarily responsible for the production
of much of the extracellular matrix proteins that consti-
tute the fibrotic scarring in fibrosis as well as the factors
which promote further proliferation and scar accumula-
tion [1]. The process of trans-differentiation and resolu-
tion (reversal) of fibrogenesis is dependent on other cells
types, notably leucocytes – which are recruited to sites of
injury – and resident macrophages (Kupffer cells) [2].
These cells produce a range of cytokines that modulate the
behaviour of myofibroblasts and may ultimately regulate
the process of fibrosis.
Nuclear receptors are transcription factors frequently con-
trolled by the binding of ligands. The pregnane X receptor
(PXR) is a nuclear receptor whose transcriptional function
is regulated by pregnane steroids, bile acids and some
drugs [3-5]. The rodent PXR ligand pregnenolone 16α car-
bonitrile (PCN) inhibits liver fibrogenesis in rodents [6,7]
and similar effects are seen with human PXR activators
and human myofibroblasts, in vitro [8]. The role of the
PXR in the PCN-dependent inhibition of liver fibrosis was
confirmed using mice with a disrupted PXR gene [6].
However, HSC trans-differentiation, in vitro, was still
inhibited by PCN despite an absence of PXR expression
within the cells (as determined by RT-PCR) and in HSCs
isolated from mice with a disrupted gene [6]. Previous
work has shown that PCN competes with the specific-sat-
urable binding of progesterone or the synthetic glucocor-
ticoid dexamethasone to "low affinity glucocorticoid
binding site" (LAGS) protein in rat liver microsomes [9-
11]. We therefore hypothesized that an additional target
for PCN in liver myofibroblasts is the LAGS.
The identity of the LAGS has yet to be determined
although it shows similar – but not identical binding
characteristics – to a steroid binding activity to which the
progesterone receptor membrane component 1
(PGRMC1) may be associated [10-14]. There are 2
PGRMC genes in humans and rodents that code for ~28
kDa proteins. The proteins have a single N-terminal mem-
brane spanning domain and do not show significant
homology with other gene super-families such as nuclear
receptors [12].
PGRMC1 has been shown to bind haem [13] but it
remains contentious as to whether the protein directly
binds steroids, as suggested by Peluso et al [14], or is a
component of a complex that binds steroids. Our data
with the human PGRMC1 suggest that phosphorylation
of the protein or a component of the binding complex
may be important for efficient steroid binding and may
explain the difficulties of reconstituting steroid binding,
when the protein is purified or over-expressed in mamma-
lian cells [12]. Nonetheless, these data are limited and the
identity of the binding protein remains to be unambigu-
ously demonstrated.
Recent evidence suggests, however, that PGRMC1 binds to
cytochrome P450s and functions to facilitate cytochrome
P450-mediated metabolism of sterol biosynthesis [15].
Interestingly, PGRMC1 stably binds to cytochrome P450
51A1 [15], an isoform that has been shown to be
expressed in activated human liver myofibroblasts [16].
We therefore hypothesized that PCN mediates its PXR-
independent mechanism of inhibiting myofibroblast
trans-differentiation/proliferation via a LAGS/PGRMC
interaction. To test this hypothesis, rat PGRMC1 was
cloned and expressed and binding of PCN to the protein
or a complex containing this protein confirmed. Through
a series of established in vitro screens, a putative ligand for
rat and human PGRMC1-associated complex – that was
not also a PXR activator – was identified and shown to
potently inhibit rat and human liver myofibroblast trans-
differentiation and proliferation, in vitro. However, this
compound failed to show any anti-fibrogenic activity in
an in vivo model of liver fibrosis because the target
PGRMC1 was not expressed by myofibroblasts, in vivo.
Results
The PGRMC1 is expressed in rat and human HSCs and 
myofibroblasts
Quiescent HSCs were isolated from normal rat liver or
from histologically normal margins of human liver tissue
resected because of the presence of a secondary tumour.
When placed in the appropriate culture conditions, these
cells trans-differentiate into myofibroblasts, reminiscent
of the process that occurs in the liver in response to
chronic liver damage [1]. Figure 1a shows that both quies-
cent rat HSCs and myofibroblasts expressed rPGRMC1
mRNA and protein at similar levels to rat hepatocytes.
Quiescent rat HSCs also expressed the HC5 truncated var-
iant of rPGRMC1 previously identified in kidney and
blood [17] although expression was repressed and unde-
tectable in myofibroblasts (Fig. 1b). Figure 1c shows that
both quiescent human HSCs and myofibroblasts from 2Page 2 of 19
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Rat and human HSCs and myofibroblasts express PGRMC1 in vitroFigure 1
Rat and human HSCs and myofibroblasts express PGRMC1 in vitro. Left panel, RT-PCR analysis for rPGRMC1 in rat 
cells and tissues as indicated using primer sequences and conditions as outlined in methods section. T6 cells are a rat hepatic 
stellate cell line [47] (a). Right panel, Western blot of the indicated cell types for rPGRMC1 using the anti-IZAb (a). RT-PCR 
products from the indicated cell types with and without digestion with the restriction enzyme Nci-I as indicated. rPGRMC1 
PCR product does not contain an Nci-I site whereas the truncated HC5 variant contains a single site and is cleaved [17] (b). 
Left panel, RT-PCR analysis for hPGRMC1 in human cells using primer sequences and conditions as outlined in methods sec-
tion. Senescent myofibroblasts had ceased proliferation (typically at passage 3–5) (c). Right panel, Western blot of the indicated 
anonymised donor cells for hPGRMC1 using the anti-IZAb (c). Results typical of a least 3 independent experiments and/or ani-
mals except right panel (c), 2 separate human donors.

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an increased expression in myofibroblasts compared to
the quiescent HSCs they were derived from.
Expression of the rat progesterone receptor membrane 
component 1 (rPGRMC1) leads to steroid binding activity 
that interacts with PCN
It has been known for many years that the liver expresses
LAGS activity [9-11,18-20]. Affinity purification of steroid
binding proteins suggests that this activity is associated
with the PGRMC1 protein (originally termed ratp28 [21],
25-Dx [22] or IZA [23] in rat and hpr6.6 in the human
[24] on the basis of limited N-terminal amino acid
sequencing).
To formally test whether the expression of rPGRMC1
leads to the presence of a steroid binding activity, the full
length cDNA for rPGRMC1 was cloned from rat myofi-
broblasts and expressed in COS-7 cells. Figure 2 demon-
strates that the pSG5-rPGRMC1 construct directed the
expression of a protein of approximately 28 kDa that
accumulated in extra-nuclear cell fractions (Fig. 2a). The
antibody employed also detected a protein of 28 kDa in
hepatocytes which was up-regulated by several LAGS lig-
ands (Fig. 2b) and was located in the extra-nuclear com-
partment (Fig. 2c). Receptor-ligand binding studies
indicate that specific binding of dexamethasone was
observed in COS-7 cells transfected with the pSG5-
rPGRMC1 construct but not in cells transfected with an
empty (pSG5) or pcDNA3.1e-LacZ vector (Fig. 2d). There-
fore, the rPGRMC1 gene encodes a protein that either
binds dexamethasone or combines with COS-7 proteins
to form a dexamethasone binding complex.
Competition studies with cold potential competitors were
performed to determine whether the rPGRMC1-associ-
ated binding activity also binds PCN. Although expres-
sion of rPGRMC1 was highly effective in COS-7 cells, the
reliable detection of dexamethasone binding activity
required such high amounts of transfected total COS-7
cell protein, that it was not feasible to perform wide rang-
ing studies to determine affinities of dexamethasone and
competitors. However, PCN as well as several other com-
pounds, previously reported to compete with dexametha-
sone for binding to rat liver microsomes [9], were ligands
on the basis of significant competition with dexametha-
sone for binding to the COS-7 cell extracts in which
rPGRMC1 protein was over-expressed (Fig. 2e).
Identifying novel ligands for the rPGRMC1-associated 
binding site activity through LAGS binding site activity
The low expression of binding site activity in rPGRMC1-
transfected COS-7 cells and relatively high level of non-
specific binding in extracts (~50% of specific and non-spe-
cific binding), precluded this system from extensive and
effective screening for novel rPGRMC1 ligands. However,
the binding of dexamethasone to rat liver microsomes
(LAGS activity) gave reproducible saturable binding char-
acteristics with a kD of 51 nM and maximal binding site
concentration of 8.3 pmoles/mg of microsomal protein
(Fig. 3a); was subject to relatively low non-specific bind-
ing (~5% of specific and non-specific binding); was suffi-
ciently abundant and binding was competed by
progesterone and a range of other ligands (Fig. 3b, Table
1), but not by the sigma receptor ligand haloperidol [25].
Early work by Meyer et al identified a progesterone bind-
ing protein in pig liver microsomes with no competition
for binding by dexamethasone (IC50% > 100 μM) [26], but
competition by haloperidol [27]. There may be species
differences between pig and rat which makes comparison
complicated. However, a sigma-related binding site has
been shown to be expressed in rat liver microsomes,
which binds both progesterone and haloperidol [28]. Our
data suggest that dexamethasone and progesterone share
a binding site in rat liver microsomes, but on the basis that
there is no competition for binding by haloperidol, this is
not the sigma-related binding site. Therefore, the use of
dexamethasone as a ligand for the LAGS is preferred over
progesterone.
A range of substituted progestins were consequently
screened for their ability to compete with dexamethasone
for binding to rat liver microsomes and the results dem-
onstrate binding of progestins was critically dependent on
the presence of a keto group at position 3 (Additional file
1). Substituting the hydrogen at position 6 with bulkier
groups markedly reduced affinity, whereas substitution of
the hydrogen at position 11 had less effect on LAGS bind-
ing (Additional file 1). Alterations at position 17 also
appeared to have less effect on affinity as long as the C17
chain was 1 or 2 carbons in length (Additional file 2).
The position of the methyl group in dexamethasone was
critical for binding to LAGS, since betamethasone – which
only differs from dexamethasone in the configuration of
the methyl group at position 16 – had an approximately
100 fold lower affinity for binding (Additional file 2). The
moieties at position 17 also appear to be important for
dexamethasone binding, since both small and bulky
group substitution prevented binding (Additional file 2).
Screening rPGRMC1-associated binding site activity/LAGS 
ligands for PXR agonism in rat and human hepatocytes
The canonical function of the PXR is a ligand-dependent
transcriptional regulation of cytochrome P450 3A
(CYP3A) genes, notably hepatic CYP3A1/3A23 and
CYP3A4 genes in rat and human hepatocytes, respectively
[4,5]. Screening the panel of ligands for CYP3A induction
showed that the classic rat PXR activators PCN, dexameth-
asone and betamethasone induced CYP3A1/3A23 expres-Page 4 of 19
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expression as expected [6]), whereas none of the other
compounds markedly affected levels relative to untreated
controls (Fig. 4a). In human hepatocytes, the potent
human PXR activator rifampicin induced CYP3A4 expres-
sion as previously reported [29], whereas none of the
other compounds showed any evidence of induction
except methylprednisolone (Fig. 4b).
Screening rPGRMC1 associated binding site activity/LAGS 
ligands for their ability in inhibit rat and human HSC trans-
differentiation/proliferation into myofibroblasts
HSCs are a major source of liver myofibroblasts in chronic
liver injury and undergo a phenotypically-similar process
of trans-differentiation in vitro when cultured on plastic in
serum-containing medium [1]. Early screening for poten-
tial anti-fibrogenic compounds is commonly performed
using this in vitro system [1]. PCN inhibited trans-differen-
tiation as previously reported [6], whereas the other
potent PXR activators were less effective (Fig. 5a). Interest-
ingly, non-physiologically high levels of progesterone
markedly inhibited rat HSC trans-differentiation, whereas
substitution at the 11 position of progesterone had mini-
mal effects on rPGRMC1 binding (Additional file 1) but
abrogated the inhibitory effects of progesterone on trans-
differentiation (Fig. 5a). A number of other compounds
were also able to inhibit the trans-differentiation of rat
HSCs (Fig 5a). However, when examined using human
HSCs, only the PXR activator rifampicin (as previously
reported [8]), progesterone, 11β hydroxyprogesterone,
and 4 androstene-3-one 17β-carboxylic acid methyl ester
(4A3COOHmethyl) showed significant inhibitory activ-
ity on trans-differentiation (Fig. 5b and 6).
Examination of myofibroblast expression of the major
pro-fibrogenic cytokine TGFβ; the fibrogenic TIMP1 and
collagen 1A1 mRNAs in human myofibroblasts treated
with selected compounds showed that the PXR activator
rifampicin (as previously reported [8]) and the PGRMC1
ligand 4A3COOHmethyl inhibited the expression of all
mRNAs, whereas other PGRMC1 ligands were less effec-
tive (Fig. 6c).
Effect of administration of 4A3COOHmethyl in an animal 
model of liver fibrosis
We selected 4A3COOHmethyl for use in an in vivo study
for anti-fibrogenic activity, since this compound showed
no activity as a PXR activator in either rat or human; com-
peted with dexamethasone for binding to LAGS and was
effective as a potential anti-fibrogenic in rat and human
screens, in vitro. Since there was no information in the lit-
erature regarding any potential adverse effects of
Expression of rPGRMC1 results in dexamethasone binding activityFigure 2 (see previous pag )
Expression of rPGRMC1 results in dexamethasone binding activity. Western blot for rPGRMC1 in various cell frac-
tions using the anti-IZ Ab in COS-7 cells transfected with the indicated construct. All lanes were loaded with 10 μg protein/
lane. Note, HC5 is a truncated form of rPGRMC1 cloned from rat kidney [17] (a). Western blot for rPGRMC1 using the anti-
IZ Ab and CYP2E1 (lower blot). Rat hepatocytes were cultured for 24 hours to allow attachment (T0) and then treated for 24 
hours with the indicated ligand or ethanol vehicle prior to analysis. Each lane contains 10 μg total protein/well, typical of 3 sep-
arate experiments (b). Confocal microscopy of rat hepatocytes demonstrating non-nuclear location of PGRMC1 and CYP2E1 
(c). 200 × 106 COS-7 cells were transfected with pSG5-rPGRMC1, pSG5 or pcDNA3.1e/lacZ and 13,000 g cell extracts pre-
pared and incubated with radiolabelled dexamethasone as outlined in methods section. Supernatant dpm after charcoal dextran 
treatment to remove free radioligand is given in dpm after normalisation of protein for total (specific and non-specific) – white 
bars; and non specific (by co-incubation of 1000-fold molar excess unlabelled dexamethasone) – black bars. The percentage of 
cells that stained positive for beta galactosidase activity (grey bars) was determined in situ in separate wells by examining at 
least 5 randomly selected low power fields. Data are the mean and standard deviation of at least 3 separate determinations 
from the same experiment, typical of 2 separate experiments (d). 200 × 106 COS-7 cells were transfected with pSG5-
rPGRMC1. Dexamethasone binding activity was determined in whole COS-7 cells as outlined in methods section and in the 
presence of the indicated concentration of unlabelled potential competitor. Specific binding was determined by co-incubation 
of replicates also containing unlabelled 1000-fold molar excess of unlabelled dexamethasone. Typically, non specific binding 
accounted for between 40–60% of total binding of radioligand. Data are the mean and standard deviation of 3 separate deter-
minations from the same experiment, typical of 3 separate experiments. Control is the mean and standard deviation specific 
activity of 3 determinations from the same experiment after subtraction of non-specific binding. The percent of binding in the 
presence of unlabelled competitors was determined after subtraction of non-specific binding. Data are typical of at least 2 sep-
arate experiments (e).
Table 1: IC50% values for competing radiolabelled 
dexamethasone from specific binding to rat liver microsomes.
Cold Competitor IC50% (10-6 M)
dexamethasone 0.098 ± 0.003
progesterone 0.081 ± 0.010
clotrimazole 40 ± 12
metyrapone 310 ± 52
haloperidol > 10000
Data are the mean and standard deviation of at least 3 separate 
microsomal (isolated from different animals) determinations.Page 6 of 19
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was initially undertaken, in which adult male rats were
administered 4A3COOHmethyl for 3 days at up to 100
mg/kg body weight by i.p. injection. Twenty four hours
after the final treatment, liver serum enzyme levels and
liver pathology were examined and no adverse effects
were observed (data not shown).
To examine the effects of 4A3COOHmethyl on fibrosis,
adult male rats were treated with 20 mg/kg body weight
by i.p. injection every week during an 8 week twice weekly
treatment with CCl4, to generate liver fibrosis. A reduced
dose of 20 mg/kg body weight was chosen because the
compound was to be administered to rats with compro-
mised liver function. To avoid potential interactions with
CCl4, toxicity (i.e., reductions in CCl4 hepatotoxicity that
could be misinterpreted as anti-fibrogenic effects),
4A3COOHmethyl was not administered within a 48 hour
period of CCl4 administration. Previous work has estab-
lished that a similar dose of PCN – using the same dosing
regimen – is sufficient to modulate fibrosis in animal
models of fibrosis [6].
Figure 7a indicates that 4A3COOHmethyl administration
did not affect serum levels of ALT after 8 weeks confirming
that 4A3COOHmethyl did not inhibit the toxicity of
CCl4. However, immunohistochemical α-smooth muscle
actin staining for liver myofibroblasts (data not shown),
determination of collagen 1a1 mRNA levels (Fig. 7b) and
a staining for scarring extracellular matrix protein (Fig. 7c
and 7d) indicate that 4A3COOHmethyl also did not sig-
nificantly affect fibrosis severity. Liver sections were there-
fore immunostained for the presence of rPGRMC1 in vivo
using the IZAb. Figures 8a and 8b (high power) indicates
that rPGRMC1 expression showed an enhanced centrilob-
ular pattern of expression in hepatocytes with clear evi-
dence of expression in non-parenchymal cells such as
quiescent HSCs in control liver sections (Fig. 9a), but not
in bile duct epithelium (Fig. 8a). However, in CCl4-
treated rat liver sections, there was little evidence for
expression of rPGRMC1 in cells within the scar region
other than likely non-specific binding of secondary anti-
body to occasional inflammatory cells, whereas hepato-
cytes showed enhanced expression (Fig. 8a and 8b). To
firmly establish that rat liver myofibroblasts in vivo do
not express rPGRMC1, fibrotic liver sections were co-
stained for the expression of α-smooth muscle actin and
rPGRMC1. Figure 9b and 9c shows that there was no co-
staining of α-smooth muscle actin in liver myofibroblasts
with rPGRMC1, which was restricted to hepatocytes in
fibrotic liver sections. Identical staining was obtained in
sections from animals treated with CCl4 or CCl4 and
4A3COOHmethyl (data not included).
Discussion
Steroid hormone interaction with nuclear receptor pro-
teins has been characterized over several decades. Steroids
pass through plasma and/or nuclear membranes and
interact with intracellular receptor proteins from the ster-
oid/nuclear receptor gene super-family (such as the PXR),
representing the canonical (genomic) mode of action for
steroid hormone signalling [30]. Those proteins are lig-
and-modulated transcription factors and interact with
specific DNA "response element" sequences as part of a
co-ordinated regulation of gene expression [30]. In this
way, steroid hormones modulate the expression of genes
containing the required response element within their
promoters in those cells which express the binding
nuclear receptor. Nuclear receptors are associated with
soluble fractions of cell. Nevertheless, steroids also inter-
act in a specific and saturable manner with proteins in cell
membranes [31]. The identity of these proteins (including
PGRMC1) has only recently been determined and their
function(s) remain to be fully established [32]. Over the
years, it has been proposed that those proteins are associ-
ated with the non-genomic effects of steroid hormone
action [32]. Steroid hormone-mediated changes in gene
expression typically take in the order of hours for a change
Radiolabelled dexamethasone interacts in a specific and saturable manner with rat liver microsomes and binding is competed by select d compoundsFigur  3 (see previous p ge)
Radiolabelled dexamethasone interacts in a specific and saturable manner with rat liver microsomes and bind-
ing is competed by selected compounds. Male rat liver microsomes were incubated in duplicate with increasing concen-
trations of radiolabelled dexamethasone (ligand) with or without excess unlabelled dexamethasone and allowed to reach 
equilibrium on ice. A small volume of each incubation was removed to determine the total ligand concentration ([L0]) prior to 
removal of free unbound ligand by dextran/charcoal adsorption. Specifically bound ligand at equilibrium ([LRe]) was calculated 
by subtracting radioactive counts present in samples which also contained excess unlabelled dexamethasone after dextran-
charcoal adsorption (and was typically < 5%). Free ligand concentration at equilibrium was calculated by subtracting specifically 
bound ligand at equilibrium from the total ligand concentration (i.e. [L0] - [LRe]) and assumes receptor-ligand stoichiometry of 
1:1. Results typical of six separate preparations (a). Male rat liver microsomes were incubated with 50 nM [3H] dexamethasone 
as outlined in methods section with or without excess unlabelled dexamethasone (to determine non-specific binding) or a 
range of unlabelled compounds (added with ethanol vehicle such that final ethanol concentration was 1%, also present in con-
trols). After overnight incubation on ice, free ligand was removed by dextran-charcoal adsorption and specifically bound radi-
olabelled dexamethasone determined (b).Page 8 of 19
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Screening for PXR activators in rat and human hepatocytes via CYP3A inductionFigure 4
Screening for PXR activators in rat and human hepatocytes via CYP3A induction. Rat hepatocytes were isolated 
and cultured as outlined in methods section. After 24 hours of culture (T0), hepatocytes were treated for a further 24 hours 
with 10 μM of the indicated compound from a 1000 fold ethanol-solvated stock (except PCN, which was added to give 20 μM 
from a DMSO-solvated stock). Equivalent ethanol (0.1% v/v) and DMSO (0.5% v/v) vehicles are included. Cells were then ana-
lyzed for expression of the indicated protein by Western blotting, 10 μg total protein/lane. Results are typical of at least 3 sep-
arate experiments (a). Human hepatocytes were treated essentially as for rat hepatocytes except that all compounds were 
prepared as ethanol solvated stocks. Cells were then analyzed for expression of the indicated protein by Western blotting, 20 
μg total protein/lane. Results are from one donor (LH2), typical of 2 different donors (b).
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Screening for inhibitors of trans-differentiation in rat and human HSCs – Part 1Figure 5
Screening for inhibitors of trans-differentiation in rat and human HSCs – Part 1. Rat HSCs were isolated and cul-
tured for 2 days (T0) whereupon cells were treated with the indicated compound as outlined in methods section. After 9 days, 
cells were analyzed by Western blotting for α-smooth muscle actin (α-sma). Each lane contains 10 μg total protein/lane, results 
typical of at least 3 separate experiments (a). Human HSCs were treated with the indicated compound and confluence deter-
mined in randomly selected fields. Data are the mean and standard deviation confluence at day 12 of 3 separate treatment 
dishes from the same donor, typical of at least 3 separate donors (b).

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Screening for inhibitors of trans-differentiation in rat and human HSCs – Part 2Figure 6
Screening for inhibitors of trans-differentiation in rat and human HSCs – Part 2. Photomicrographs of human HSCs 
at day 12 of culture with the indicated treatment (a); levels of expression of α-smooth muscle actin (α-sma) (b) and levels of 
expression of fibrogenic marker mRNA transcripts in human HSCs after treatment selected compounds for 19 days. Data are 
the mean and standard deviation relative transcript level from 3 separate treatments on cells from the same donor, typical of at 
least 3 separate donors (c).
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4A3COOHmethyl administration and liver fibrosis in a rat CCl4 model of liver fibrosisFigure 7
4A3COOHmethyl administration and liver fibrosis in a rat CCl4 model of liver fibrosis. Four animals/group (con-
trol or 4A3COOHmethyl) or six animals/group (CCl4 or CCl4 + 4A3COOHmethyl) were treated as outlined in the Methods 
section. Mean and standard deviation serum ALT (a); Mean and standard deviation collagen 1A1 mRNA levels (b); typical views 
of liver sections stained for sirius red, with a 100 μm scale bar (b); quantitative image analysis for fibrosis – data are the mean 
and standard deviation percentage sirius red staining from at least 4 separate animals in each treatment with at least 10 ran-
domly selected fields examined for each animal (c).

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Rat liver myofibroblast do not express rPGRMC1 in vivo – Part AFigur  8
Rat liver myofibroblast do not express rPGRMC1 in vivo – Part A. Low power views (a) and high power views (b) of 
liver section immunohistochemically stained for rPGRMC1 using IZAb upper panels or identical staining without addition of 
IZAb (no 1° Ab control) from olive oil control or CCl4 treated animals (note CCl4 + 4A3COOHmethyl treated animals gave 
similar results). PT, portal tract; CV, central vein; scar, primary location of scar matrix and liver myofibroblasts; ns non-specifi-
cally bound secondary antibody.
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Rat liver myofibroblast do not express rPGRMC1 in vivo – Part BFigur  9
Rat liver myofibroblast do not express rPGRMC1 in vivo – Part B. High powered views show positive staining of non-
parenchymal cells in control liver sections (a); co-staining sections from indicated treatment groups – DNA with DAPI (blue), 
α-sma (green) and PGRMC1 with IZAb (red) with merged panel (b); high powered view of merged liver section from CCl4-
treated rat liver (c). PV, periportal venule; PA, periportal arteriole; BD, bile duct.

B
C
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(within seconds) changes in cells, such as alterations in
calcium homeostasis [32]. These effects occur too fast to
be dependent on changes in gene expression and have
been suggested to be dependent on membrane-associated
receptors and/or proteins such as PGRMC1 [32].
The data in this paper suggest that PGRMC1 is a steroid
binding protein in agreement with Peluso et al [14]. How-
ever, neither our data nor the latter authors' data demon-
strate binding with purified PGRMC1, leaving open the
possibility that PGRMC1 is required for a functional ster-
oid binding complex but may not be the direct binding
protein within the complex. Procaryotic expression of
PGRMC1 has failed to generate a binding species
although this may be explained by the requirement for a
eucaryotic-specific folding and/or post-translation modi-
fication. We have previously shown that phosphorylation
of a truncated human PGRMC1 leads to steroid binding
activity [9], and this may be crucial for effective and effi-
cient binding of steroids by PGRMC1 or an associated
protein. However, we have been unable to efficiently gen-
erate a binding protein in COS-7 cells most likely because
the phosphorylation event is not efficiently mimicked or
is rapidly reversed by de-phosphorylation. Accordingly,
we had to rely on liver microsomal LAGS activity for our
screening assays.
The function of PGRMC1 remains elusive and therefore
the role that this protein plays in liver myofibroblasts can
only be postulated. PGRMC1 shares close homology with
the yeast protein Dap1p which is required for cell cycle
progression following DNA damage [33]. PGRMC1 also
protects cancer cells from oxidative damage [34]. More
recently, PGRMC1 has been shown to bind haem and to
modulate the activity of some cytochrome P450s [15].
The data in this paper demonstrate that a steroidal ligand
for the LAGS/PGRMC1 potently inhibits the trans-differ-
entiation of HSCs to fibrogenic myofibroblasts in vitro.
The pivotal signal that directs HSC trans-differentiation
has not been unequivocally identified; nonetheless, oxi-
dative stress is known to be a promoter and possibly an
essential component [1]. Since PGRMC1 protects cancer
cells from oxidative stress [34], it is tempting to speculate
that 4A3COOHmethyl modulates the ability of PGRMC1
to function in this capacity. Cytochrome P450s and the
cytochrome P450 electron transport chain are a promi-
nent source of reactive oxygen species, since their catalytic
function involves the NAD(P)H-dependent splitting of
molecular oxygen with concomitant mono-oxygenation
of substrate and reduction to water. Cytochrome P450s
such as the CYP51A1 – which are expressed in liver myofi-
broblasts in vitro [16] – may therefore be a source of reac-
tive oxygen species that trigger HSC differentiation.
Modulating the generation of reactive oxygen species
through PGRMC1-mediated effects on cytochrome P450s
may then be the mechanism of action by which
4A3COOHmethyl and other PGRMC1/LAGS ligands
operate. Alternatively, 4A3COOHmethyl may modulate
the levels of sterols generated by CYP51A1 or other cyto-
chrome P450s that regulate trans-differentiation.
The 4A3COOHmethyl administration had no detectable
effect on fibrosis, in vivo, using the rat CCl4 model of liver
fibrosis. There are many potential reasons why this com-
pound failed to demonstrate an anti-fibrogenic effect in
vivo. The compound may not have achieved the required
therapeutic concentrations in vivo because of absorption,
distribution, metabolism or excretion effects that are not
mimicked in the in vitro model employed. However, it is
essential in these studies, to avoid any interaction with the
injuring agent to avoid inadvertently identifying an anti-
fibrogenic when in fact the agent is simply reducing
injury. This consideration restricts potential anti-fibro-
genic dosing periods to an extent although studies using
the same protocol have been adequate to demonstrate
anti-fibrogenic efficacy with other compounds [6,35]. It is
notable that liver myofibroblasts are located adjacent to
hepatocytes, in vivo, the most metabolically active cells
toward drugs/xenobiotics in the body [1]. Hepatocytes
actively sequester and metabolize a vast array of drugs/
xenobiotics and therefore may reduce sufficiently the lev-
els of anti-fibrogenic required to modulate myofibroblast
activity. Thus, there may be a need in many instances for
drugs to be directly targeted to myofibroblasts for the drug
to be an effective anti-fibrogenic. In this respect, a number
of targeting therapies are being developed including mod-
ified albumins that are sequestered by myofibroblasts [36-
39] to antibodies that interact with a surface antigen on
myofibroblasts [40-42]. However, evidence presented in
this paper strongly suggest that PGRMC1 is not expressed
in rat liver myofibroblasts, in vivo. Myofibroblasts may be
derived from a number of sources in vivo including HSCs,
the bone marrow and from epithelial-mesenchymal tran-
sition [1,43], whereas myofibroblasts generated in vitro
are primarily derived from vitamin A-loaded quiescent
HSC. So, few liver myofibroblasts may be derived from
HSCs in the CCl4 model. A more likely scenario, however,
is that HSC-derived myofibroblasts are not identical to
liver myofibroblasts, in vivo. Previous work by others has
shown that culture activation of HSCs into myofibroblasts
only partially reproduced the gene expression changes
observed during BDL- and CCl4-induced activation [44].
Conclusion
Although 4A3COOHmethyl potently inhibited HSC
trans-differentiation to pro-fibrogenic myofibroblasts in
vitro without activating the PXR, it failed to inhibit liver
fibrosis in an in vivo rat model. The cause of the disparity
between in vitro and in vivo responses toPage 15 of 19
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of expression of the PGRMC1 target in liver myofibrob-
lasts in vivo in contrast to in vitro activated myofibroblasts.
This underscores the importance of animal models for
testing potential anti-fibrogenics and suggests that con-
firming the presence of drug targets in vivo (including
human diseased liver tissue) may assist in the develop-
ment of effective anti-fibrotic drugs for clinical use. These
data also demonstrate that the anti-fibrogenic effects of
PCN in vivo are likely mediated entirely via the PXR.
Methods
Reagents
All compounds in Additional files 1 and 2 were purchased
from Steraloids (Rhode Island, USA) except dexametha-
sone, betamethasone, progesterone, androstenedione and
testosterone which were purchased from the Sigma
Chemical Company (Poole, UK). All other reagents were
from local commercial sources and were of the highest
purity available.
Isolation and culture of HSCs
HSCs were isolated from rats (250–300 g body weight,
Harlan, UK) by sequential pronase/collagenase perfusion
of the liver followed by density gradient centrifugation
and elutriation as previously outlined [45]. Human HSCs
were isolated by an essentially similar procedure [46]
using discarded tissue from patients undergoing a hepate-
ctomy with patient consent and ethical approval by the
Grampian Regional Ethical Committee. HSCs were
seeded onto plastic culture dishes and cultured in Dul-
becco's modified Eagle Medium (DMEM) containing 4.5
g/l of glucose and supplemented with 5% or 16% (v/v)
fetal calf serum (for rat or human respectively), 80 μ/ml
penicillin, 80 μg/ml streptomycin and 32 μg/ml gentamy-
cin. Additional treatments were made by addition of com-
pounds in an ethanol vehicle (stock solutions at 1000×
final concentration). Ethanol at 0.1% (v/v) acted as con-
trol. Frequency of treatment (3 treatments per week/2
medium changes per week), as previously described [8].
Isolation and culture of hepatocytes
Rat hepatocytes were prepared by collagenase perfusion,
essentially as previously described [46,47], and cultured
in William's Medium E supplemented with 1 μg/ml
bovine insulin, 10% foetal calf serum (FCS), 80 μ/ml pen-
icillin and 80 μg/ml streptomycin on collagen type-I
coated 6 well plates (BD Biosciences). After 2 hours, the
medium was renewed without FCS and insulin supple-
mentation and thereafter changed daily with renewed
media additions where indicated. Human hepatocytes
were obtained from the UK Human Tissue Bank under
MREC approval and were cultured in William's Medium E
supplemented with 80 u/ml penicillin and 80 μg/ml
streptomycin on collagen type-I coated plates. Addition
treatments were made daily from ethanol stocks, essen-
tially as outlined for HSCs above.
Confocal microscopy
Cultured cells were fixed, as previously outlined [42], and
incubated with primary antibodies – IZAb [23] and anti-
CYP2E1 – followed by rhodamine red-conjugated anti-
mouse IgG and FITC-conjugated anti-rabbit IgG (pur-
chased from the Jackson Labs) to detect bound primaries,
respectively. Cells were then examined using an Olympus
BX50W1 microscope fitted with a Biorad μRadiance con-
focal scanning system and green (emission 515–530 nm)
and red (emission > 570 nm) images captured. Staining
without addition of primary antibodies was used to deter-
mine background fluorescence.
RT-PCR and cloning rPGRC1
RNA was isolated using TRIzol (Invitrogen, Paisley, UK)
according to manufacturer instructions and reversed tran-
scribed using downstream primers and MMLV reverse
transcriptase (Promega, Southampton, UK). The
rPGRMC1 was amplified (35 cycles @ 52°C annealing
temperature) using ratp28US (5'-TTTGCTCCAGAGAT-
CATGGCT) and ratp28DS (5'-ACTACTCTTCAGT-
CACTCTTCCG) primers to amplify a 611 bp product. The
human PGRMC1 was amplified (35 cycles @ 44°C
annealing temperature) using hLAGSUS (5'-ATCAT-
GGCTGCCGAGGATGTG) and hHPR6.6DS (5'-CACT-
GAATGCTTTAATCATTTTTCCGGGC) primers to amplify
a 602 bp product. The rPGRMC1 PCR product includes
the full amino acid sequence of the protein and was ini-
tially inserted into the pUniblunt TOPO vector (Invitro-
gen, Groningen, The Netherlands) and sequenced to
check integrity. The sequence was identical to that previ-
ously published [21]. The rPGCMR1 insert was then sub-
cloned into the pSG5 eucaryotic expression vector (Strata-
gene, La Jolla, USA) at the EcoRI site. Correctly oriented
inserts were screened initially using BamHI and NsiI
restriction and a selected clone (pSG5-rPGRMC1) con-
firmed by sequencing.
Transfections and COS-7 cell binding assays
COS-7 cells were transfected at 30–50% confluency using
Effectene transfection reagent (Qiagen, Southampton,
UK) essentially according to the manufacturer's instruc-
tions with either pSG5 empty vector, pSG5-rPGRMC1 or
the β-galactosidase-encoding pcDNA3.1e/lacZ vector
(Invitrogen, Paisley, UK). Thirty hours after transfection,
β-galactosidase activity was determined in fixed cells,in
situ. Briefly, the culture medium was aspirated from the
dish and the cells washed twice with PBS buffer (10 mM
phosphate buffer, 2.7 mM KCl and 137 mM NaCl pH
7.4). The cells were then fixed in 2% (w/v) formaldehyde/
0.2% (w/v) glutaraldehyde for 15 minutes followed by 3
washes in PBS buffer. The cells were then incubated withPage 16 of 19
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ide) in PBS containing 4 mM K3Fe(CN)6, 4 mM
K4Fe(CN)6 and 2 mM MgCl2. After incubation for 2 hours
at 37°C, β-galactosidase positive (blue) cells were identi-
fied by microscopic examination of 10 randomly selected
fields. For the determination of steroids binding activity,
the medium was discarded and the cells were washed
twice with ice-cooled HBSS (0.14 M NaCl, 5.4 mM KCl,
0.34 mM Na2HPO4, 0.44 mM KH2PO4, 5.6 mM glucose,
1 mM CaCl2, 6 mM HEPES, 4 mM NaHCO3 pH 7.4). Cells
were then harvested using a cell scraper and pelleted by
centrifugation. Steroid binding activity was determined in
homogenised COS-7 cell extracts prepared by re-suspend-
ing cell pellets in 10 mM Tris, 250 mM sucrose pH 7.4
buffer and disruption using a Turrax homogenisor. The
homogenate was then centrifuged at 13,000 g for 5 min-
utes at 4°C. The supernatant was retained and assayed for
protein concentration using the method of Lowry and
binding activity using 100 nM [3H]dexamethasone with
or without excess unlabelled dexamethasone. After over-
night incubation on ice, free ligand was removed by char-
coal dextran adsorption and bound ligand determined in
supernatants by liquid scintillation essentially, as previ-
ously described [9-11].
Westerns
Western Blotting was performed after SDS-PAGE under
reducing conditions using a MiniP2 Biorad electrophore-
sis apparatus. Protein was transferred onto nitrocellulose
and blocked overnight with 3% (w/v) milk protein/0.3%
(w/v) Tween 20. Antibody raised against the C-termini of
CYP3A1/3A23 (IITGS) was used, as described previously
[11]. The anti-α-smooth muscle actin and anti-β-actin
(cross reacts with all actin isoforms) antibodies were pur-
chased from the Sigma Chemical Co (Poole, UK) and
Chemicon (Chandlers Ford, UK), respectively. The anti-
CYP2E1 and anti-LAGS (IZ-Ab) antibodies were obtained
from Prof. M. Ingelman-Sundberg, Karolinska Institutet,
Stockholm, Sweden, and Prof. Gavin Vinson, Queen Mary
College, London, UK. After incubation with primary anti-
bodies, blots were incubated with the appropriate horse-
radish peroxidase conjugated anti-IgG antibody.
Detection was accomplished using chemiluminescence
with the ECL kit (Amersham).
Microsomal receptor-ligand binding assay
Rat liver microsomes were prepared and incubated with
[3H] dexamethasone to determine LAGS activity, as previ-
ously outlined [9-11]. In brief, rats were anaesthetized
with pentobarbital and a 16G cannula inserted into the
hepatic portal vein and secured. The blood was cleared
from the liver by pumping ice-cooled perfusion buffer
(0.14 M NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4, O.44
mM KH2PO4, 15.7 mM NaHCO3 and 5.6 mM glucose, pH
7.4) through the liver at 50 mls per minute. The liver was
then excised and chopped roughly with ice-cooled TS
buffer (10 mM Tris/HCl pH 7.4 containing 250 mM
sucrose) and disrupted using a Potter-Elvehjem homoge-
nisor. The resultant homogenate was then centrifuged at
12,000 g for 20 minutes at 4°C and the supernatant
retained and centrifuged at 100,000 g for 60 minutes at
4°C. The resultant "microsomal" pellet was re-suspended
in fresh TS buffer and re-centrifuged at 100,000 g to
obtain a washed microsomal pellet. The pellet was finally
re-suspended in TS buffer supplemented with 5 mM dithi-
othreitol and used immediately (on ice at all times) by
addition of [3H]dexamethasone with or without excess
unlabelled dexamethasone. After overnight incubation on
ice, free ligand was removed by charcoal dextran adsorp-
tion and bound radioligand determined in supernatants
by liquid scintillation, essentially as previously described
[9-11].
Quantitative RT-PCR
Quantitative transcript expression was examined after
reverse transcription (using a Taqman reverse transcrip-
tion kit (Applied Biosystems)) using a PE Applied Biosys-
tems ABI7700 and PE Applied Biosystems Gene
Expression Assay™, incorporating sequence-specific for-
ward, reverse and fluorescently labelled probes (see Table
2).
In vivo animal study and tissue analysis
Rats were administered CCl4 mixed 1:1 (v/v) with olive oil
– 2 ml/kg body weight by i.p. injection – twice weekly for
8 weeks to generate liver fibrosis [46]. Control animals
were administered olive oil alone (1 ml/kg body weight).
Once a week between CCl4 treatment, rats received
4A3COOHmethyl (20 mg/kg body weight). After 8 weeks,
animals were killed by cervical dislocation and samples of
various tissues removed and fixed in 10% formalin in
PBS. Blood was allowed to clot prior to centrifugation to
obtain serum for analyses. Serum ALT levels, α-smooth
muscle actin immunostaining and sirius red staining were
performed as previously outlined [6,46].
Table 2: qRT-PCR kits used in these studies.
Transcript mRNA Applied Biosystems Primer Kit
Human
18S rRNA Hs99999901_sl
TGF-β1 Hs00171257_ml
TIMP1 Hs00171558_ml
COL1A1 Hs00164004_ml
Rat
GAPDH 4352338E
COL1A1 Rn00801649_g1Page 17 of 19
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